Table 1.
Clinical Trials Included in MaGIC Study
| Trial | National Group | Trial Eligibility Criteria | Treatment Regimen | Cycles |
No. of Patients | |
|---|---|---|---|---|---|---|
| Length (days) | No. | |||||
| GC115 | UK | All patients with MGCTs | Etoposide 120 mg/m2 on days 1 to 3, bleomycin 15 IU/m2 on day 2, cisplatin 100 mg/m2 on day 1 | 21 | n + 2* | 14 |
| GC22 | UK | All patients with MGCTs | JEB | 21 | n + 2* | 135 |
| INT-0106/POG9048/CCG-889110 | US | Stage II testicular and stage I to II ovarian tumors | PEB | 21 | 4 (+ 2 if PR) | 33 |
| INT-0097/POG9049/CCG-88823 | US | Stage III to IV gonadal and extragonadal tumors | PEB v HDPEB | 21 | 4 (+ 2 if PR) | 250 |
| P974912 | US | Stage III to IV extragonadal tumors | Amifostine 825 mg/m2 on days 1 to 5 plus HDPEB | 21 | 4 (+ 2 if PR) | 26 |
| AGCT01P116 | US | Stage III to IV extragonadal tumors | C-PEB | 21 | 4 (+ 2 if PR) | 14 |
| AGCT013217 | US | Stage I to III ovarian, stage I to IV testicular, and stage I to II extragonadal tumors | Compressed PEB | 21 | 3 (+ 3 if PR) | 47 |
Abbreviations: C-PEB, cyclophosphamide, cisplatin, etoposide, and bleomycin; CCG, Children's Cancer Group; HDPEB, cisplatin, etoposide, and bleomycin; JEB, carboplatin, etoposide, and bleomycin; MaGIC, Malignant Germ Cell International Collaborative; MGCT, malignant germ cell tumor; PEB, cisplatin, etoposide, and bleomycin; POG, Pediatric Oncology Group; PR, partial response.
*
No. of courses to marker normalization.